Wolfe Research analyst Andy Chen downgraded 89bio (ETNB) to Peer Perform from Outperform without a price target after the company entered into an agreement to be acquired by Roche (RHHBY) for $14.50 per share in cash, plus a non-tradeable contingent value right to receive certain milestone payments of up to an aggregate of $6.00 per share in cash.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB: